Protalix BioTherapeutics (PLX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 25, 2026, with voting on key proposals including director elections, executive compensation, stock incentive plan amendments, and auditor ratification.

• Shareholders of record as of April 30, 2026, are eligible to vote, with 80,571,642 shares outstanding.

• Voting can be done by mail, phone, internet, or in person, and a quorum requires at least one-third of outstanding shares.

Voting matters and shareholder proposals

• Election of eight directors for a one-year term.

• Advisory vote on executive compensation (say-on-pay).

• Approval of amendments to the 2006 Stock Incentive Plan, increasing available shares from 17,475,171 to 20,975,171 and extending the plan to April 23, 2036.

• Ratification of Kesselman & Kesselman as independent auditor for fiscal year 2026.

• Shareholder proposals for the 2027 meeting must be submitted by January 1, 2027.

Board of directors and corporate governance

• All eight director nominees are current board members with diverse backgrounds in biotech, finance, and business development.

• Majority of board members are independent per NYSE American and SEC standards.

• Board committees include Audit and Finance, Compensation, and Nominating, all with independent members.

• Non-management directors meet separately at least twice per year.